Christopher K. Murray - Mar 1, 2024 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Signature
/s/ Melissa Masse, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
Mar 1, 2024
Transactions value $
-$58,157
Form type
4
Date filed
3/6/2024, 10:41 AM
Previous filing
Mar 1, 2024
Next filing
Mar 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Award $0 +12.5K +51.03% $0.00 37K Mar 1, 2024 Direct F1
transaction BPMC Common Stock Sale -$58.2K -621 -1.68% $93.65 36.4K Mar 4, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Award $0 +25K $0.00 25K Mar 1, 2024 Common Stock 25K $95.12 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction involved the Reporting Person's receipt of grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan.
F2 Effected pursuant to a trading plan adopted on June 5, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F3 This option vests with respect to 1/48th of the shares underlying the option on April 1, 2024 and as to an additional 1/48th of the shares underlying the option each month thereafter.